Evaluation of elabela, apelin and nitric oxide findings in maternal blood of normal pregnant women, pregnant women with pre-eclampsia, severe pre-eclampsia and umbilical arteries and venules of newborns
- 7 May 2019
- journal article
- research article
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 39 (7) , 907-912
Abstract
Pre-eclampsia is multisystem metabolic diseases, commonly accompanied by hypertension and proteinuria, which are among the important causes of maternal and perinatal mortality and morbidity worldwide. In a pre-eclampsia animal model study in the last year, Elabela (ELA) infusion was reported to correct hypertension and proteinuria and to normalise the birth weights of the offspring. Therefore, our main goal in this human study is to compare ELA, apelin (APLN) and nitric oxide (NO) levels in the maternal blood of pregnant women with pre-eclampsia and severe pre-eclampsia and in their newborns’ venous-arterial cord blood with maternal blood of healthy pregnant women and their newborns’ venous-arterial cord blood. Thirty controls, 28 pre-eclampsia and 24 severe pre-eclampsia cases and their newborns participated in this study. Maternal blood and newborn venous-arterial cord blood samples were collected from these patients. ELA, APLN and NO levels in these samples were measured by ELISA method. When the maternal blood ELA, APLN and NO amounts were compared with control groups, there was a significant decrease in both pre-eclamptic and severe pre-eclamptic women and this was more prominent in the women with severe pre-eclampsia. When ELA, APLN and NO levels in the newborn venous-arterial cord blood of control group was compared with that of severe pre-eclamptic and pre-eclamptic women; it was parallel with maternal findings. ELA, APLN and NO levels appear to play a role in the pathophysiology of pre-eclampsia. It is predicted that if these molecules, which are reduced due to pre-eclampsia and severe pre-eclampsia, are brought to physiological limits in the future; pre-eclampsia related maternal and perinatal mortality and morbidity can be reduced.Keywords
This publication has 28 references indexed in Scilit:
- ELABELA: A Hormone Essential for Heart Development Signals via the Apelin ReceptorDevelopmental Cell, 2013
- Decreased expression of apelin in placentas from severe pre-eclampsia patientsHypertension in Pregnancy, 2013
- Progress towards Millennium Development Goals 4 and 5 on maternal and child mortality: an updated systematic analysisThe Lancet, 2011
- Decreased Maternal Plasma Apelin Concentrations in PreeclampsiaHypertension in Pregnancy, 2010
- Acute Cardiovascular Effects of Apelin in HumansCirculation, 2010
- Genetic variants in the apelin system and blood pressure responses to dietary sodium interventions: a family-based association studyJournal Of Hypertension, 2010
- Nitric Oxide in the Vasculature: Where Does It Come From and Where Does It Go? A Quantitative PerspectiveAntioxidants & Redox Signaling, 2008
- Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studiesBMJ, 2005
- Spiral Artery Blood Flow in the Central and Peripheral Areas of the Placental Bed in the Second TrimesterObstetrics & Gynecology, 1995
- Severe pre-eclampsia and infants of very low birth weight.Archives of Disease in Childhood, 1987